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Coordinated by the Centre on Drug Policy Evaluation, Toronto?s drug checking service launched in 
October 2019 to:
- Offer people who use drugs timely and detailed information on the contents of their drugs, helping 
them to make more informed decisions
- Publicly share information on Toronto?s unregulated drug supply, helping harm reduction workers 
and clinicians tailor the care they provide to people who 
use drugs
- Advocate for services and safer alternatives for people 
who use drugs
Toronto?s drug checking service is free, anonymous, and 
available to everyone. Accepted samples include a substance 
(a small amount of a powder, pill, blotter, or liquid) and 
paraphernalia after it?s been used (a cooker, filter, or leftover 
liquid from a syringe).
Samples are collected at five harm reduction agencies in 
Toronto where supervised consumption services are offered:
-  Parkdale Queen West Community Health Centre (Queen West site) 
-  South Riverdale Community Health Centre 
-  The Works at Toronto Public Health 
-  Moss Park Consumption and Treatment Service 
-  Parkdale Queen West Community Health Centre (Parkdale site) 
Five days per week, samples are transported to a nearby laboratory at the Centre for Addiction and 
Mental Health or St. Michael?s Hospital to be analyzed using mass spectrometry technologies (gas 
chromatography and liquid chromatography).
Results are available within a business day or two and are communicated to clients by harm reduction 
staff in person or by phone. Along with these results, clients receive tailored harm reduction supports, 
guidance, and referral to services (e.g., supervised consumption, naloxone training, primary health 
care).
Onsite drug checking using other technologies is offered at participating harm reduction agencies 
(currently limited to benzodiazepine test strips). 
Toronto?s drug checking service helps to uncover the makeup of Toronto?s unregulated drug supply by 
combining results from samples checked and posting them online every other week. 
About Toronto?s Drug Checking Service
What's the Unregulated 
Drug Supply?
The unregulated drug supply 
includes illegal drugs, as well 
as legal drugs diverted from 
regulated markets for sale 
through criminal channels. 
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2020 marks the first full year of operation for Toronto?s drug checking service. Operational 
accomplishments achieved in 2020 included: 
- Checking and providing individual results for 1,657 samples
- Publishing 28 reports on combined results from samples checked, including a detailed report on 
samples checked between October 2019 ? March 2020
- Releasing 5 formal alerts related to noteworthy drugs found unexpectedly in Toronto?s unregulated 
drug supply:
-  ACHMINACA and AMB-FUBINACA (synthetic cannabinoid-related) 
-  Carfentanil 
-  Xylazine (animal tranquilizer) 
- Launching Toronto?s drug checking service interactive website to publicly share timely information 
on Toronto?s unregulated drug supply
- Expanding the service by 2 additional harm reduction agencies to collect samples and 
communicate results to clients: Moss Park Consumption and Treatment Service and the Parkdale 
site of Parkdale Queen West Community Health Centre
- Publishing 2 academic articles related to scientific research on Toronto?s drug checking service: 
-  Evaluating networked drug checking services in Toronto, Ontario: study protocol and rationale
-  Detection of synthetic cannabinoid adulteration in the unregulated drug supply in three Canadian 
settings
- Developing a method to determine the absolute quantity of five drugs that pose the highest risk for 
overdose and/or contamination (rollout in 2021) 
- Introducing benzodiazepine test strips onsite at participating harm reduction agencies 
- Over 450 people joining the mailing list for Toronto?s drug checking service 
- Over 3,000 unique visitors to Toronto?s drug checking service interactive website
Service Operations: 2020 at a Glance
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When the COVID-19 state of emergency was declared in March 2020, physical distancing and service 
restrictions limited clients? ability to access the harm reduction agencies where Toronto?s drug checking 
service is offered. 
As a result, we experienced a 62% decrease in sample collection between February and April 2020. 
Sample collection recovered by July, with an average of 189 samples checked each month from July to 
December. 
Changes in Toronto?s unregulated drug supply coincide with the COVID-19 pandemic ? most notably, 
an escalation in the contamination of fentanyl. Increases in benzodiazepine-related drugs, synthetic 
cannabinoids, carfentanil, xylazine (animal tranquilizer), as well as several fentanyl-related drugs 
presenting in expected fentanyl samples were observed. This increase in fentanyl contamination 
corresponds with a record number of both fatal and non-fatal overdoses at local, provincial, and 
national levels. 
In order to better understand the relationship between these co-existing crises, the Centre on Drug 
Policy Evaluation was funded by the Canadian Institutes of Health Research to rapidly assess the 
impact of the COVID-19 pandemic on people who inject drugs in Toronto, with a focus on clinical and 
social outcomes, service utilization, and trends in the unregulated drug supply.
COVID-19: Implications for Service Delivery 
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Results from Samples Checked
January 1 ? December 31, 2020
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- 1,657 samples were checked: 59% were substances and 
41% were used paraphernalia 
- 53% of samples checked were expected to be fentanyl 
- Expected fentanyl samples were varying shades of purple, 
pink, red, blue, green, yellow, or white
- 7% of expected fentanyl samples were known to be 
associated with an overdose: 98% of those samples 
contained fentanyl and 77% of those samples contained 
both fentanyl and a benzodiazepine-related drug
- Xylazine, a tranquilizer used by veterinarians, was first 
identified in September and presented in 7% of expected 
fentanyl samples in October to December
- Carfentanil resurged in September, presenting in 2% of 
expected fentanyl substances in July to December
- 63% of expected fentanyl substances contained 
benzodiazepine-related drugs in October to December, 
compared to 39% in January to March
- 31% of expected heroin substances contained fentanyl
- Presence of the two most common cocaine adulterants ? 
phenacetin and levamisole ? increased by more than 100% 
between January and December in expected cocaine 
substances 
- Substances expected to be opioids continue to be 
significantly more contaminated than other expected drugs 
? meaning there were a lot of other drugs found in each 
expected opioid substance:
- 5% of fentanyl substances contained only fentanyl
- No heroin substances contained only heroin
Meanwhile: 
- 78% of ketamine substances contained only ketamine 
- 75% of methamphetamine substances contained only 
methamphetamine
- 45% of cocaine substances contained only cocaine
Unexpected Fentanyl in 
Other  Drug Types
In 2020, fentanyl was found 
in 1 of 61 expected MDMA 
substances, 3 of 103 
expected methamphetamine 
substances, and 4 of 29 
expected benzodiazepine 
substances checked by 
Toronto?s drug checking 
service. While we have heard 
about fentanyl 
contamination in other drug 
types from the community 
of people who use drugs in 
Toronto, we are not, 
currently, seeing a trend 
toward increasing fentanyl 
adulteration of cocaine, 
crack cocaine, 
methamphetamine, or other 
stimulants, psychedelics, or 
depressants. There is 
general agreement in the 
drug checking community 
that the unexpected 
presence of fentanyl in other 
drug types is accidental and 
a product of cross 
contamination. That said, 
unexpected fentanyl poses 
significant risk, especially for 
those who do not regularly 
use opioids. It?s always a 
good idea to get your drugs 
checked.
Key Findings: January 1 ? December 31, 2020 
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Two types of samples are accepted by Toronto?s drug checking service: substances and used 
paraphernalia. Between January 1 ? December 31, 2020, 1,657 samples were checked: 59% (985) were 
substances and 41% (672) were used paraphernalia.
Checked Samples by Sample Type
Substances could be a small amount of powder, a crushed bit of a pill, blotter, or a small amount 
of liquid.
Used paraphernalia could be a used cooker or filter, or leftover liquid from a syringe.
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When a sample is submitted to be checked, the drug that sample is expected to contain is recorded 
(and is known as the ?expected drug?). This graph shows the expected drug for the 1,657 samples 
checked between January 1 ? December 31, 2020.
Checked Samples by Expected Drug
Other expected drugs include: 3-MeO-PCE, 3-MeO-PCP, 4-AcO-DET, 4-AcO-DMT, 4-AcO-MET, 4-FA, 
4-HO-MET, 4-HO-MiPT, 4-MPM, 5-APB/6-APB, 5-MeO-DiPT, 5-MeO-DMT, 5-MeO-MiPT, Adderall, 
AMT, codeine, DiPT, DMT, DPT, down, etaqualone, GHB, hydromorphone, iohexol, MDA, mescaline, 
methylone, modafinil, morphine, naloxone, O-DSMT, O-PCE, OxyContin, Percocet, phenidate, Soma, 
Vyvanse, and Z-drugs.
Unknown includes samples that did not have a recorded expected drug.
Polysubstance includes samples that had two or more expected drugs (e.g., fentanyl and 
methamphetamine).
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Of the 985 substances checked between January 1 ? December 31, 2020, 31% (308) were expected to 
be fentanyl.
Expected Fentanyl Substances
Presence of fentanyl in expected fentanyl substances (308)
Expected fentanyl substances containing fentanyl and other drugs (266)
In substances expected to be fentanyl that contained no fentanyl, the most commonly found drugs 
were caffeine, heroin, and cocaine. 
Opioids
86% (266) of expected fentanyl substances checked contained fentanyl and other drugs, including: 
- 91% (242) contained caffeine
- 56% (150) contained a benzodiazepine-related drug:
- 53% (141) contained etizolam (!)
- 5% (13) contained flualprazolam (!)
- 1% (3) contained flubromazolam (!)
- Less than 1% (1) contained deschloretizolam (!)
- 42% (113) contained despropionyl fentanyl (4-ANPP) (!)
- 8% (21) contained acetyl fentanyl (!)
- 7% (19) contained phenacetin (!)
- 3% (7) contained furanyl UF-17 (opioid-related) (!)
- 2% (5) contained carfentanil (!)
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Of note from expected fentanyl samples that were used paraphernalia (562)
Unexpected noteworthy drugs (!) found only in expected fentanyl samples that were used 
paraphernalia included: several other fentanyl-related drugs (butyryl fentanyl, furanylethyl fentanyl, 
parafluorofentanyl, valeryl fentanyl, and variations of these drugs), benzodiazepine-related drugs 
(alprazolam (Xanax), clonazepam, and meclonazepam), AB-FUBINACA (synthetic cannabinoid-related), 
levamisole, and xylazine. 
- 1% (3) contained a synthetic cannabinoid-related drug:
- 1% (2) contained AMB-FUBINACA (!)
- Less than 1% (1) contained ACHMINACA (!)
- 1% (2) contained methyl fentanyl (!) 
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Of the 985 substances checked between January 1 ? December 31, 2020, 3% (29) were expected to be 
heroin.
Expected Heroin Substances
Presence of heroin in expected heroin substances (29)
Expected heroin substances containing heroin and other drugs (21)
In substances expected to be heroin that contained no heroin, the most commonly found drugs were 
caffeine, cocaine, despropionyl fentanyl (4-ANPP) (!), and fentanyl (!).
72% (21) of expected heroin substances checked contained heroin and other drugs, including:  
- 95% (20) contained caffeine
- 76% (16) contained morphine
- 67% (14) contained codeine
- 38% (8) contained dextromethorphan
- 24% (5) contained cocaine
- 19% (4) contained fentanyl (!)
- 5% (1) contained etizolam (benzodiazepine-related) (!)
- 5% (1) contained levamisole (!)
- 5% (1) contained phenacetin (!)
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Of the 985 substances checked between January 1 ? December 31, 2020, 1% (12) were expected to be 
Percocet:
- 58% (7) contained acetaminophen
- 50% (6) contained oxycodone
- 17% (2) contained fentanyl (!)
Expected Percocet Substances
Of the 985 substances checked between January 1 ? December 31, 2020, less than 1% (4) were 
expected to be carfentanil:
- None contained carfentanil
- 75% (3) contained fentanyl (!)
- 25% (1) contained despropionyl fentanyl (4-ANPP) (!)
- 25% (1) contained etizolam (benzodiazepine-related) (!)
- 25% (1) contained furanyl UF-17 (opioid-related) (!)
Expected Carfentanil Substances
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Of the 985 substances checked between January 1 ? December 31, 2020, 14% (138) were expected to 
be cocaine.
Expected Cocaine Substances
Presence of cocaine in expected cocaine substances (138)
Expected cocaine substances containing cocaine and other drugs (74)
In substances expected to be cocaine that contained no cocaine, the only drug found was 
acetaminophen. 
Stimulants
54% (74) of expected cocaine substances checked contained cocaine and other drugs, including:  
- 42% (31) contained phenacetin (!)
- 41% (30) contained levamisole (!)
- 3% (2) contained benzocaine (!)
- 1% (1) contained etizolam (benzodiazepine-related) (!) 
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Of the 985 substances checked between January 1 ? December 31, 2020, 10% (103) were expected to 
be methamphetamine. 
Expected Methamphetamine Substances
Presence of methamphetamine in expected methamphetamine substances (103) 
Expected methamphetamine substances containing methamphetamine and other drugs (11) 
In substances expected to be methamphetamine that contained no methamphetamine, the most 
commonly found drug was caffeine. 
11% (11) of expected methamphetamine substances checked contained methamphetamine and other 
drugs, including:    
- 36% (4) contained cocaine
- 27% (3) contained caffeine
- 9% (1) contained etizolam (benzodiazepine-related) (!)
- 9% (1) contained fentanyl (!)
- 9% (1) contained levamisole (!)
- 9% (1) contained phenacetin (!)
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Of the 985 substances checked between January 1 ? December 31, 2020, 3% (26) were expected to be 
crack cocaine. 
Expected Crack Cocaine Substances
Presence of cocaine in expected crack cocaine substances (26) 
Expected crack cocaine substances containing cocaine and other drugs (19) 
In substances expected to be crack cocaine that contained no cocaine, there were no other commonly 
found drugs.
73% (19) of expected crack cocaine substances checked contained cocaine and other drugs, 
including:     
- 89% (17) contained phenacetin (!)
- 26% (5) contained levamisole (!)
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Of the 985 substances checked between January 1 ? December 31, 2020, 2% (16) were expected to be 
amphetamine.
Expected Amphetamine Substances
Presence of amphetamine in expected amphetamine substances (16) 
In substances expected to be amphetamine that contained no amphetamine, the most commonly 
found drug was methamphetamine.
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Of the 985 substances checked between January 1 ? December 31, 2020, 6% (61) were expected to be 
MDMA. 
Expected MDMA Substances
Presence of MDMA in expected MDMA substances (61) 
Expected MDMA substances containing MDMA and other drugs (22) 
In substances expected to be MDMA that contained no MDMA, the most commonly found drugs were 
MDA and methamphetamine. 
Psychedelics
36% (22) of expected MDMA substances checked contained MDMA and other drugs, including:    
- 64% (14) contained MDA
- 32% (7) contained MDEA
- 9% (2) contained etizolam (benzodiazepine-related) (!)
- 5% (1) contained fentanyl (!)
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Of the 985 substances checked between January 1 ? December 31, 2020, 6% (55) were expected to be 
ketamine:
- 96% (53) contained ketamine
Expected Ketamine Substances
Of the 985 substances checked between January 1 ? December 31, 2020, 2% (23) were expected to be 
LSD:
- 95% (22) contained LSD
- 4% (1) contained levamisole (!)
Expected LSD Substances
Of the 985 substances checked between January 1 ? December 31, 2020, 2% (16) were expected to be 
a 2C class drug: 
- 75% (12) contained a 2C class drug
Expected 2C class drugs included 2C-B, 2C-C, 2C-D, 2C-P, 2C-T-4, and 2C-T-5.  
Expected 2C Class Substances
Of the 985 substances checked between January 1 ? December 31, 2020, 1% (14) were expected to be 
GHB:
- 100% (14) contained GHB
- 7% (1) contained etizolam (benzodiazepine-related) (!)
- 7% (1) contained phenacetin (!)
Expected GHB Substances
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Of the 985 substances checked between January 1 ? December 31, 2020, 3% (29) were expected to be 
a benzodiazepine-related drug: 
- 76% (22) contained a benzodiazepine-related drug
- 14% (4) contained fentanyl (!)
- 3% (1) contained despropionyl fentanyl (4-ANPP) (!)






2C class drugs A family of psychedelic drugs with varying potencies
AB-FUBINACA A synthetic cannabinoid, manufactured to be like the main 
psychoactive component in cannabis, THC, considered to be 
ultrapotent
Acetyl fentanyl An active fentanyl-related drug, considered to be more potent 
than heroin and less potent than fentanyl
ACHMINACA A synthetic cannabinoid, manufactured to be like the main 
psychoactive component in cannabis, THC, considered to be 
ultrapotent 
Alprazolam (Xanax) A high-potency, short-acting benzodiazepine used to treat 
anxiety
AMB-FUBINACA A synthetic cannabinoid, manufactured to be like the main 
psychoactive component in cannabis, THC, considered to be 
ultrapotent
Benzocaine A local anesthetic (numbing medication) used to relieve pain 
that can reduce the amount of oxygen carried by a person's 
blood throughout their body
Butyryl fentanyl An active fentanyl-related drug, considered to be less potent 
than fentanyl
Carfentanil An active fentanyl-related drug, considered to be ultrapotent: 
approximately 100 times stronger than fentanyl, 4,000 times 
stronger than heroin, and 10,000 times stronger than morphine
Clonazepam A high-potency, long-acting benzodiazepine used to prevent and 
control seizures and treat panic attacks
Deschloroetizolam A benzodiazepine-related drug, structurally similar to etizolam, 
although half as potent and lasting twice as long
Despropionyl fentanyl (4-ANPP) An inactive fentanyl-related drug, which is an impurity found in 
fentanyl preparations 
Dextromethorphan A medication used to relieve cough caused by the common cold 
or flu
Etizolam A short-acting benzodiazepine-related drug, used in some 




Flualprazolam A high-potency, short-acting benzodiazepine-related drug, 
similar to alprazolam (Xanax)
Flubromazolam A high-potency, long-acting benzodiazepine-related drug
Furanyl UF-17 An opioid-related drug with unknown potency and effects
Furanylethyl fentanyl An active fentanyl-related drug
Levamisole A medication used to treat worm infections in animals, pulled 
from the Canadian market in the early 2000s, that has been 
associated with skin sores and a reduction of infection-fighting 
white blood cells
Lorazepam (Ativan) A high-potency, short-acting benzodiazepine used to treat 
anxiety
Meclonazepam A benzodiazepine used to treat parasitic worms
Methyl fentanyl An active fentanyl-related drug, considered to be significantly 
more potent than fentanyl
Parafluorofentanyl An active fentanyl-related drug, considered to be similarly potent 
to fentanyl
Phenacetin A pain-relieving, fever-reducing medication, pulled from the 
Canadian market in the 1970s for its association with kidney 
and bladder cancers
Valeryl fentanyl An active fentanyl-related drug, considered to be more potent 
than morphine and much less potent than fentanyl
Xylazine A tranquilizer typically used by veterinarians on horses, deer, 
dogs, and cats for sedation, muscle relaxation, and pain relief
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Checking your drugs is one way to reduce the harms associated with using drugs from an unregulated 
supply. Toronto?s drug checking service is offered alongside other harm reduction services in Toronto, 
including supervised consumption. These services have the most impact when used together.
1.  Carry and be trained to use naloxone. Naloxone, also known by the brand name Narcan, is a drug 
that can temporarily reverse an opioid overdose. Naloxone can be picked up for free from your local 
harm reduction agency or pharmacy and free training is available online. Consider carrying multiple 
doses of naloxone.
2.  Get your drugs checked before using. In Toronto, drug checking services are offered at Moss Park 
Consumption and Treatment Service, Parkdale Queen West Community Health Centre (Queen West 
and Parkdale sites), South Riverdale Community Health Centre, and The Works at Toronto Public 
Health. You can also check your drugs after you have used them by submitting paraphernalia, like a 
cooker or a filter.
Other drug checking services in Canada include British Columbia Centre on Substance Use Drug 
Checking Service, Get Your Drugs Tested, and Vancouver Island Drug Checking Project.
3.  Use at a supervised consumption site or overdose prevention site. Here is a list of sites that offer 
supervised consumption in Toronto and an interactive map of sites that offer supervised 
consumption across Canada.
4.  Use with someone else and take turns spotting for each other. A buddy system is safer than using 
alone. Stay 6 feet from your buddy if you are not from the same household to avoid passing 
COVID-19.
5.  If you must use alone, let someone know before you use. Call someone you know and have them 
stay on the phone with you while you use. Tell them your address and keep your door unlocked. If 
you are in Ontario, you could call the Overdose Prevention Line at 1-888-853-8542. The National 
Overdose Response Service is available to anyone in Canada and can be reached at 
1-888-688-NORS (6677). BeSafe is an app that can be downloaded on your phone and provides 
another way to let someone know before you use.
6.  Do a small test dose first.
7.  Call 911 in an overdose situation. The Good Samaritan Drug Overdose Act provides legal protection 
from drug-related charges for carrying drugs for personal use and other simple possession 
offences.
8. If your drugs did not contain what you were expecting, consider talking to the person you got your 
drugs from, or get your drugs from another source if possible.
9.  If you use opioids, learn more about safer supply programs. Safer supply programs provide 
people who use drugs with prescribed alternatives to opioids obtained from the unregulated supply. 
Tips & Help
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Here is an interactive map of sites that operate safer supply projects across Canada and a toolkit to 
advocate for safer opioid supply programs. 
Alternatively, you could speak to a health care provider about options like methadone or suboxone. 
Your local harm reduction agency could likely refer you to methadone or suboxone providers. Or you 
could contact ConnexOntario.
10. Visit your local harm reduction agency for free supplies, including safer injection and smoking 
equipment. Here is a list of harm reduction agencies in Ontario.
11. If you are a youth who uses drugs, connect with organizations like the Trip! Project. The Trip! 
Project is a Toronto-based youth-led harm reduction health information service for the dance music 
scene and youth who use drugs.
12. Stay informed by signing up to receive alerts, reports, and other information on the unregulated 
drug supply from Toronto?s drug checking service. Results from samples checked by Toronto?s drug 
checking service are combined and shared online every other week. You can also sign up for 
Toronto Public Health?s mailing list to receive alerts and other drug-related information.
13. Act to advance the health, human rights, and dignity of people who use drugs by connecting with 
and supporting advocacy organizations such as Toronto Harm Reduction Alliance, Canadian 
Association of People who Use Drugs, Canadian Students for Sensible Drug Policy, and Canadian 
Drug Policy Coalition.
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As part of our evolution as a pilot program, we are learning how to most accurately report drugs found 
through analysis to clients and the public. This means our reporting will change and improve over time. 
Toronto?s drug checking service is currently the only drug checking service in Canada that uses gas 
chromatography- and liquid chromatography-mass spectrometry as the primary instruments for 
analysis. Gas chromatography- and liquid chromatography-mass spectrometry analysis are typically 
conducted within a laboratory, meaning results take longer to report and are not immediately available 
at the point of collection. 
The benefits of using these instruments are their comprehensive and regularly updated libraries, 
allowing them to detect hundreds if not thousands of drugs, as well as their ability to detect very trace 
amounts of drugs. This is particularly beneficial for drug market monitoring of noteworthy drugs that 
typically only present in trace amounts but can increase risk of overdose or adverse effects, such as 
benzodiazepine-related drugs and carfentanil in opioids or fentanyl in stimulants and psychedelics. 
The drawbacks of using such sensitive instruments are that some of the drugs they report are inactive 
or drug precursors and their inclusion in reporting may not add value to clients? and the public?s 
understanding of their own drug samples or the unregulated drug supply.
A role of Toronto?s drug checking service is to translate analysis results to meet the needs of different 
audiences. Part of this involves simplifying results by reducing the number of drugs reported directly to 
clients and on our website. Examples of drugs we no longer plan to share with clients or on our website 
include norfentanyl, which is a fentanyl-related drug that is believed to be an inactive precursor, in 
fentanyl samples or benzoylecgonine, an inactive metabolite of cocaine, in cocaine samples. 
For routine reporting to clients and on our website, we will focus on drugs for which there is information 
available on their potency or effects, and drugs that are a known potentiator or psychoactive filler. 
Notes
Throughout this report and our website, we use (!) to signify an unexpected noteworthy drug. 
?Noteworthy drugs? are drugs that:
- Are linked to overdose or other adverse effects
- Are highly potent or related to highly potent drugs
- May not be desired by some clients 
Noteworthy drugs are flagged when they are unexpectedly found in checked samples.
Reporting Standards for Drugs Found
Noteworthy Drugs (!) 
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It is important to understand the limitations of this drug checking service:
1. Checking a sample cannot guarantee that a drug is safe to use.
2. The results for a sample may not represent the rest of the 
drugs that sample was taken from (this is known as the 
Chocolate Chip Cookie Effect). 
3. Due to technological limitations, some drugs may be 
missed.
4. Due to technological limitations, non-drug fillers are not 
reported. This could include non-drug fillers that may be 
dangerous, such as bacteria, metals, pesticides, or 
inorganic salts. Other non-drug fillers may not be 
dangerous, such as sugar or laxatives.
5.  Results for used paraphernalia have other limitations:
- Paraphernalia, like cookers, are often re-used. The 
mass spectrometry technologies used for Toronto?s 
drug checking service are so sensitive that very trace 
amounts of drugs may be found. This means that 
when paraphernalia is re-used, drugs from past use 
may present in the results for the sample that is 
being checked. This can interfere with current drug 
market monitoring, which is why we rely only on 
substance samples when reporting trends.  
- Fatty acids are more commonly found in samples that 
are taken from used paraphernalia, most likely from oils on skin. These fatty acids can interfere 
with the mass spectrometry analysis. It may be difficult to see past them to determine which 
drugs are present.
For these reasons, checking substances instead of used paraphernalia is preferred.
Limitations of Toronto?s Drug Checking Service
What's the Chocolate Chip 
Cookie Effect?
The results for a sample that 
is checked may not represent 
the rest of the drugs that 
sample was taken from. You 
can imagine your drugs as a 
chocolate chip cookie. If you 
check a piece of the cookie 
that is only dough, your 
results may not identify 
chocolate as present. Mixing 
a powder or scratching 
different parts of a pill when 
preparing a sample can 
increase the 
representativeness of your 
sample.
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The Centre on Drug Policy Evaluation strives to improve community health and safety by conducting 
research and outreach on best practices in drug policy. We work collaboratively with governments, 
affected communities, and civil society to guide effective and evidence-based policy responses to 
substance use. The Centre on Drug Policy Evaluation is housed within MAP Centre for Urban Health 
Solutions at St. Michael?s Hospital, a site of Unity Health Toronto, in Toronto, Canada.
Learn more about Toronto?s drug checking service. Like us on Facebook, 
facebook.com/centreondrugpolicyevaluation, and follow us on Twitter, @drugpolicyctr.
Questions or comments? We?d love to hear from you. You can reach us at drugchecking@cdpe.org.
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